Compare Forgent Power Solutions Inc. Class A Common Stock (FPS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Forgent Power Solutions Inc. Class A Common Stock vs Tango Therapeutics Inc. — how do they compare? Forgent Power Solutions Inc. Class A Common Stock trades at $31.61 (market cap $9.93B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Forgent Power Solutions Inc. Class A Common Stock is far larger — about 2.6× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Forgent Power Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Forgent Power Solutions Inc. Class A Common Stock for 0 Days and Tango Therapeutics Inc. for 0 Days on average.
| FPS | TNGX | |
|---|---|---|
Market Cap | $9.93B | $3.75B |
Volume | 7,516,726 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $64.59 | $32.90 |
52-Week Low | $27.97 | $7.50 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.54B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Forgent Power Solutions (FPS) trades at $36.17, down 2.48% on the day, following a strong earnings-driven rally. The stock shows neutral technical signals with support at $35 and resistance at $37. Recent Q2 2026 earnings beat expectations with EPS of $0.25 versus $0.24 expected, continuing a pattern of quarterly outperformance. The company reported record $3 billion backlog and strong data center demand driving growth.
FPS presents significant upside potential with analyst consensus target of $55.20 (52.9% upside) and 85.7% buy ratings. However, high valuation multiples (P/E 120.57, P/S 6.21) and negative 2025 net income of -$6.17M create valuation concerns. Key risks include execution on $3B backlog and potential overvaluation amid AI infrastructure hype.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Forgent Power Solutions Inc. Class A Common Stock
Forgent Power Solutions designs and manufactures electrical distribution equipment, including transformers, switchgear, transfer switches, and prefabricated power systems, for data centers, the power grid, and industrial facilities, manufacturing across multiple product categories in-house through a network of manufacturing campuses in US.
Read more on FPS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
